Keith Woods Sells 10,220 Shares of Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) COO Keith Woods sold 10,220 shares of the business’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $49.57, for a total value of $506,605.40. Following the transaction, the chief operating officer directly owned 620,055 shares of the company’s stock, valued at approximately $30,736,126.35. The trade was a 1.62% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Stock Up 0.6%

Shares of NASDAQ SRRK opened at $48.10 on Wednesday. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.41. The company has a market cap of $5.53 billion, a price-to-earnings ratio of -14.02 and a beta of 0.68. Scholar Rock Holding Corporation has a 12 month low of $27.07 and a 12 month high of $51.63. The stock has a 50-day moving average price of $46.17 and a two-hundred day moving average price of $42.20.

Scholar Rock (NASDAQ:SRRK) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.10. During the same period last year, the company posted ($0.64) EPS. As a group, analysts forecast that Scholar Rock Holding Corporation will post -3.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on SRRK. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Scholar Rock in a research note on Tuesday, March 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a research note on Thursday, January 22nd. JPMorgan Chase & Co. upped their price objective on Scholar Rock from $47.00 to $50.00 and gave the company an “overweight” rating in a research note on Monday, March 16th. Truist Financial upped their price objective on Scholar Rock from $44.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, March 3rd. Finally, UBS Group began coverage on Scholar Rock in a research note on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price objective for the company. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $55.40.

Hedge Funds Weigh In On Scholar Rock

Hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. increased its position in Scholar Rock by 161.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 713,988 shares of the company’s stock valued at $26,589,000 after purchasing an additional 440,401 shares during the period. Moody Aldrich Partners LLC increased its position in Scholar Rock by 53.5% during the 3rd quarter. Moody Aldrich Partners LLC now owns 101,742 shares of the company’s stock valued at $3,789,000 after purchasing an additional 35,481 shares during the period. Voya Investment Management LLC increased its position in Scholar Rock by 18.1% during the 3rd quarter. Voya Investment Management LLC now owns 443,155 shares of the company’s stock valued at $16,503,000 after purchasing an additional 67,839 shares during the period. HighVista Strategies LLC increased its position in Scholar Rock by 90.8% during the 3rd quarter. HighVista Strategies LLC now owns 59,573 shares of the company’s stock valued at $2,218,000 after purchasing an additional 28,343 shares during the period. Finally, Nan Fung Trinity HK Ltd. acquired a new stake in Scholar Rock during the 3rd quarter valued at approximately $1,402,000. 91.08% of the stock is currently owned by institutional investors.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).